45
Participants
Start Date
June 1, 2015
Primary Completion Date
April 25, 2016
Study Completion Date
April 25, 2016
GSK1325756 (Danirixin)
It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
Placebo To Match GSK1325756
It will be supplied as capsule shaped white film coated placebo tablet for oral use
Oseltamivir Phosphate
It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
Placebo To Match Oseltamivir Phosphate
It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
GSK Investigational Site, Moloto South
GSK Investigational Site, Middelburg
GSK Investigational Site, Reiger Park
GSK Investigational Site, Johannesburg
GSK Investigational Site, Brookvale
GSK Investigational Site, Johannesburg
GSK Investigational Site, Baulkham Hills
GSK Investigational Site, Hinchinbrook
GSK Investigational Site, Liverpool
GSK Investigational Site, Tarneit
GSK Investigational Site, Noble Park
GSK Investigational Site, Pakenham
GSK Investigational Site, Berwick
GSK Investigational Site, Lynbrook
GSK Investigational Site, Kedron
GSK Investigational Site, Everton Plaza
GSK Investigational Site, Browns Plains
GSK Investigational Site, Springfield
GSK Investigational Site, Glenelg East
GSK Investigational Site, Happy Valley
GSK Investigational Site, Port Elizabeth
GSK Investigational Site, Claremont
GSK Investigational Site, Yokine
GSK Investigational Site, Morley
GSK Investigational Site, Applecross
GSK Investigational Site, Baldivis
GSK Investigational Site, Palmetto Bay
GSK Investigational Site, Marshfield
GSK Investigational Site, Oklahoma City
GSK Investigational Site, Blackfoot
GSK Investigational Site, Medford
GSK Investigational Site, Pretoria
GSK Investigational Site, Western Cape
Lead Sponsor
GlaxoSmithKline
INDUSTRY